A5001597981- Bladder and Urothelial Cancer Treatments
- Cancer Immunotherapy and Biomarkers
- Prostate Cancer Treatment and Research
- Lung Cancer Treatments and Mutations
- Urinary and Genital Oncology Studies
- Boron Compounds in Chemistry
- Colorectal Cancer Treatments and Studies
- Cancer-related gene regulation
- Hormonal and reproductive studies
- Cancer, Lipids, and Metabolism
- Ubiquitin and proteasome pathways
- Epigenetics and DNA Methylation
- Radiopharmaceutical Chemistry and Applications
- Urological Disorders and Treatments
Second Affiliated Hospital of Fujian Medical University
2025
Zhejiang Provincial People's Hospital
2015-2024
Hangzhou Medical College
2023
PURPOSE For patients with metastatic hormone-sensitive prostate cancer (mHSPC), delaying progression to castration-resistant disease is important not only for overall survival (OS) but also patients' quality of life. Darolutamide plus androgen-deprivation therapy (ADT) docetaxel improved OS versus ADT and in mHSPC. The ARANOTE trial evaluated darolutamide without chemotherapy METHODS In this global phase III trial, were randomly assigned 2:1 receive 600 mg twice daily or placebo, concomitant...
Background Post-traumatic epilepsy (PTE) is a common complication following traumatic brain injury (TBI). Early PTE refers to the appearance of seizure symptoms within 7 days injury. The glucose-to-potassium ratio (GPR) has emerged as potential biomarker for predicting risk. This study aimed evaluate association between GPR and risk PTE, assess predictive value through various analyses. Methods A total 2,049 TBI patients were included in analysis, with evaluated both continuous categorical...
2610 Background: Tislelizumab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody, has demonstrated promising efficacy in several advanced solid tumors. However, some patients (pts) do not respond or develop resistance to tislelizumab monotherapy. Lenvatinib, a receptor tyrosine kinase inhibitor targeting VEGFR 1-3, FGFR 1-4, PDGFR alpha, KIT, and RET, shown potential synergistic effect with anti-PD-1 therapy. Here, we report the primary results of phase II study evaluating...
Abstract Background Bladder cancer (BCa) is a highly malignant tumor, and if left untreated, it can develop severe hematuria tumor metastasis, thereby endangering the patient's life. The purpose of this paper was to detect expression ATAD3A in BCa research relationship between pathological features bladder prognosis patients. Methods First, normal tissues analyzed based on UALCAN Oncomine public databases. Second, 491 cases surgically resected specimens 110 adjacent were...
5059 Background: Despite DOC is recommended for chemo-naïve mCRPC pts previously treated with novel hormone therapy, prognosis remains unfavorable. Herein we report the safety, PK, and preliminary efficacy of addition REZ (a androgen receptor inhibitor) to in who had progressed after ABI. Methods: This was a multicenter, 2-part, phase 2 study. Part 1 included 3 + dose escalation expansion phase. Eligible were enrolled receive (160/240 mg, PO, QD) plus (75 mg/m , IV, D1, Q3W, up 10 cycles...